These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 21111550)

  • 61. Improving outcomes with antiplatelet therapies in percutaneous coronary intervention and stenting.
    Hobson A; Curzen N
    Thromb Haemost; 2009 Jan; 101(1):23-30. PubMed ID: 19132185
    [No Abstract]   [Full Text] [Related]  

  • 62. Aspirin for the prevention of cardiovascular morbidity.
    Sanchez-Ross M; Waller AH; Maher J; Klapholz M; Haider B; Kaluski E
    Minerva Med; 2010 Aug; 101(4):205-14. PubMed ID: 21030934
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Low-dose aspirin for primary prevention of cardiovascular disease.
    Bredie SJ; Wollersheim H; Verheugt FW; Thien T
    Semin Vasc Med; 2003 May; 3(2):177-84. PubMed ID: 15199480
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis.
    Zhang C; Sun A; Zhang P; Wu C; Zhang S; Fu M; Wang K; Zou Y; Ge J
    Diabetes Res Clin Pract; 2010 Feb; 87(2):211-8. PubMed ID: 19853947
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Should aspirin be used for the primary prevention of cardiovascular disease in the general population?
    Huang QY; Yang RQ
    Med Princ Pract; 2015; 24(2):198. PubMed ID: 25377538
    [No Abstract]   [Full Text] [Related]  

  • 66. Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events: A Systematic Review and Meta-analysis.
    Zheng SL; Roddick AJ
    JAMA; 2019 Jan; 321(3):277-287. PubMed ID: 30667501
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Aspirin resistance in diabetic patients: laboratory entity or clinical reality?].
    Legrand DA; Scheen AJ
    Rev Med Liege; 2007 Oct; 62(10):610-5. PubMed ID: 18069572
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Aspirin continues to attract research and debate, 115 years after its synthesis.
    Patrono C
    Rev Esp Cardiol (Engl Ed); 2013 Apr; 66(4):251-4. PubMed ID: 24775613
    [No Abstract]   [Full Text] [Related]  

  • 69. Bleeding risk with aspirin must be balanced against benefit.
    Harv Heart Lett; 2012 Aug; 22(12):8. PubMed ID: 23025025
    [No Abstract]   [Full Text] [Related]  

  • 70. [Aspirin for primary prevention of cardiovascular diseases in diabetic patients: focus on gender difference and insulin resistance].
    Legrand DA; Scheen AJ
    Rev Med Liege; 2006 Oct; 61(10):682-90. PubMed ID: 17209500
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The role of aspirin as antiaggregant therapy in primary prevention. An update.
    Jiménez-García N; de la Torre Lima J; García Alegría J
    Med Clin (Barc); 2019 Oct; 153(8):326-331. PubMed ID: 31521369
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Anti-platelet treatment for all diabetic patients?].
    Torres Baile JL; Ortega Sánchez G
    Aten Primaria; 2010 Apr; 42(4):241-2. PubMed ID: 19628306
    [No Abstract]   [Full Text] [Related]  

  • 73. Aspirin for the Prevention of Cardiovascular Disease and Colorectal Cancer: New Recommendations from the USPSTF.
    Owens DK
    Am Fam Physician; 2017 Feb; 95(4):222-223. PubMed ID: 28290628
    [No Abstract]   [Full Text] [Related]  

  • 74. Is low-dose aspirin safe for you? If you take daily aspirin, make sure you know why and understand the small but real bleeding risk.
    Harv Mens Health Watch; 2012 Oct; 17(3):3. PubMed ID: 23175863
    [No Abstract]   [Full Text] [Related]  

  • 75. Aspirin: its risks, benefits, and optimal use in preventing cardiovascular events.
    Park K; Bavry AA
    Cleve Clin J Med; 2013 May; 80(5):318-26. PubMed ID: 23636924
    [TBL] [Abstract][Full Text] [Related]  

  • 76.
    Fortuni F; Crimi G; Gritti V; Mirizzi AM; Leonardi S; Ferrari GM
    Eur J Prev Cardiol; 2019 Oct; 26(15):1677-1679. PubMed ID: 30744399
    [No Abstract]   [Full Text] [Related]  

  • 77. A revised health impact assessment of increased use of aspirin in Wales.
    Morgan G
    Public Health; 2012 Aug; 126(8):719-20. PubMed ID: 22613028
    [No Abstract]   [Full Text] [Related]  

  • 78. Aspirin in the primary prevention of vascular disease.
    Ambrosi P
    Lancet; 2009 Sep; 374(9693):877; author reply 879. PubMed ID: 19748391
    [No Abstract]   [Full Text] [Related]  

  • 79. Aspirin for primary prevention of cardiovascular disease in Japan.
    Morimoto T; Matsui K
    Intern Med; 2007; 46(15):1281. PubMed ID: 17675791
    [No Abstract]   [Full Text] [Related]  

  • 80. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation.
    Pignone M; Alberts MJ; Colwell JA; Cushman M; Inzucchi SE; Mukherjee D; Rosenson RS; Williams CD; Wilson PW; Kirkman MS
    Circulation; 2010 Jun; 121(24):2694-701. PubMed ID: 20508178
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.